NHS England Low Priority Treatment - omega-3 fatty acid compounds by all Sub-ICB Locations

Why it matters: Omega-3 fatty acid compounds are licensed to treat elevated triglycerides, but evidence of benefit is weak. NICE recommend that they are not prescribed for primary prevention of cardiovascular disease.

Description: Cost of omega-3 fatty acid compounds per 1000 patients

Performance: Loading...


Tagged as: Cardiovascular system, Cost Saving, Efficacy, NHS England Low Priority, NICE (or browse all measures)

Sub-ICB Locations are ordered by mean percentile over the past six months. Each chart shows the results for the individual Sub-ICB Location, plus deciles across all Sub-ICB Locations in the NHS in England.

View measure for NHS England combined →

Fetching data...

Do you need help with your analysis? Don't forget to check the FAQ page, and if you have questions.